> ## Documentation Index
> Fetch the complete documentation index at: https://docs.withdovetail.com/llms.txt
> Use this file to discover all available pages before exploring further.
# Periodic Safety Update Report
> Provide comprehensive benefit-risk analysis supporting continued device market authorization.
## Summary
The Periodic Safety Update Report (PSUR) provides a **comprehensive benefit-risk analysis** integrating clinical data, real-world evidence, and safety signals collected over a defined surveillance period. This report is specifically required for implantable devices and certain high-risk medical devices. Unlike standard post-market surveillance reports, PSURs require **comprehensive benefit-risk analysis** that integrates clinical data, real-world evidence, and safety signals to support continued market authorization.
## Why is Periodic Safety Update Report important?
Regulatory authorities mandate PSURs to ensure **ongoing benefit-risk evaluation** of medical devices based on real-world evidence. The PSUR demonstrates that your device's benefits continue to outweigh risks as clinical experience accumulates. Notified bodies use PSURs to **assess continued compliance** with essential requirements and determine whether **certificate renewals** are appropriate. Failure to provide adequate PSURs can result in **certificate suspension**, **market withdrawal**, or **additional surveillance requirements** imposed by authorities.
## Regulatory Context
While FDA doesn't specifically require PSURs, equivalent reporting may be required for:
* **Post-market surveillance studies** under 21 CFR 822 requiring benefit-risk analysis
* **Premarket Approval (PMA)** devices requiring periodic reports under 21 CFR 814.84
* **Risk Evaluation and Mitigation Strategies (REMS)** assessments
* **De Novo pathway devices** with special controls requiring surveillance
**Special attention required for:**
* **Class III devices** requiring comprehensive safety data analysis
* **Breakthrough devices** with accelerated approval pathways
* **Software as Medical Device** requiring algorithm performance monitoring
* **Combination products** requiring coordinated safety assessment
Under **EU MDR 2017/745**:
* **PSURs required** for implantable devices and Class III devices (Article 86)
* Must be submitted to **notified body** at intervals determined during conformity assessment
* **Benefit-risk analysis** must integrate all available safety and performance data
* **EUDAMED submission** required for high-risk device categories
**Special attention required for:**
* **Implantable devices** requiring annual or biennial PSURs
* **Class IIb devices** in sterile or measuring functions may require PSURs
* **Novel technologies** with limited clinical evidence requiring enhanced monitoring
* **Device grouping** justification when multiple devices covered in single PSUR
## Guide
Your PSUR must demonstrate **systematic benefit-risk evaluation** using comprehensive data analysis, statistical assessment, and clinical interpretation of accumulated evidence.
### Market Data Analysis
**Document device exposure** by providing accurate **sales volumes** and **patient exposure estimates** across different geographic regions. Use consistent metrics throughout your PSUR (devices placed on market, patient-years of exposure, or episodes of use) to enable meaningful trend analysis.
**Calculate exposure-adjusted incident rates** to account for changes in market penetration. Present data for **European Economic Area (EEA)**, **Turkey**, **Northern Ireland**, and **worldwide** markets separately to meet regulatory reporting requirements.
**Assess device lifecycle status** including first market introduction date, current market status (active, withdrawn, recalled), and any **basic UDI-DI variations** within your device family.
### Safety Data Integration
**Analyze serious incidents** using **IMDRF Adverse Event Terminology** categories covering medical device problems (Annex A), investigation findings (Annexes B-D), health effects (Annexes E-F), and component issues (Annex G). Calculate both absolute numbers and percentage rates relative to exposure.
**Evaluate trend patterns** using statistical methods to identify **clinically significant increases** in incident frequency or severity. Document whether trends represent random variation, increased reporting awareness, or genuine safety signals requiring intervention.
**Review Field Safety Corrective Actions** (FSCAs) and **Corrective and Preventive Actions** (CAPAs) implemented during the surveillance period. Assess **effectiveness** of corrective measures and whether additional actions are required.
### Clinical Evidence Evaluation
**Integrate literature findings** from your clinical evaluation activities, including new publications, clinical studies, and **state-of-the-art developments** that may affect your device's benefit-risk profile.
**Assess Post-Market Clinical Follow-up** (PMCF) data and determine whether findings require updates to your **clinical evaluation report** or **risk management file**. Document how PMCF conclusions support continued device authorization.
**Evaluate complaints and user feedback** that don't qualify as serious incidents but provide insights into device performance, user satisfaction, and **real-world effectiveness**.
### Benefit-Risk Assessment
**Conduct comprehensive benefit-risk analysis** by weighing accumulated safety data against demonstrated clinical benefits. Consider whether new evidence affects your **intended use**, **user populations**, or **clinical claims**.
**Assess data limitations** including surveillance gaps, under-reporting factors, and methodological constraints that may affect your conclusions. Demonstrate **scientific rigor** in acknowledging uncertainties while drawing appropriate conclusions.
**Determine impact on device authorization** by concluding whether your benefit-risk profile remains favorable, requires enhanced monitoring, or necessitates regulatory action such as labeling updates or design modifications.
## Example
**Scenario:** You manufacture an implantable cardiac defibrillator and prepare your biennial PSUR covering 24 months of comprehensive safety and performance monitoring across global markets.
### Periodic Safety Update Report for DefibGuard Pro ICD System
**1. Executive Summary**
This PSUR covers DefibGuard Pro ICD models DG-300 through DG-305 for the period January 1, 2023 to December 31, 2024. Analysis of 847,000 patient-years of exposure, 234 serious incidents, and comprehensive literature review confirms favorable benefit-risk profile supporting continued market authorization.
**2. Device Information and Market Data**
| Market Region | Total Devices Implanted | Patient-Years Exposure | Serious Incidents | Incident Rate per 1000 Patient-Years |
| ------------- | ----------------------- | ---------------------- | ----------------- | ------------------------------------ |
| EEA + TR + NI | 145,230 | 423,100 | 89 | 0.21 |
| Worldwide | 298,450 | 847,000 | 234 | 0.28 |
**3. Safety Analysis**
**Serious Incidents by IMDRF Category:**
* Medical Device Problems (Annex A): 156 incidents (66.7%)
* Health Effects (Annex E): 45 incidents (19.2%)
* Component Issues (Annex G): 33 incidents (14.1%)
**4. Trend Analysis**
Statistical analysis using Poisson regression showed **stable incident rates** over the surveillance period (p = 0.34). No significant trends identified requiring immediate regulatory action.
**5. Field Safety Corrective Actions**
One FSCA initiated (FSCA-2024-001) for battery longevity communication enhancement. Implementation achieved 94% user notification rate with positive user feedback.
**6. Literature and Clinical Evidence**
Review of 67 new publications confirms continued clinical effectiveness for primary prevention of sudden cardiac death. Post-market clinical follow-up data from 12,500 patients demonstrates 96.2% appropriate therapy delivery rate.
**7. Benefit-Risk Conclusion**
Based on analysis of comprehensive safety and performance data, the benefit-risk profile of DefibGuard Pro ICD System remains **favorable** with benefits continuing to outweigh risks. No regulatory action required beyond continued routine surveillance.
## Q\&A
PSURs are required for implantable devices and certain Class III devices under EU MDR. The specific reporting frequency is determined during your conformity assessment process. Typically, implantable devices require annual or biennial PSURs depending on risk profile and clinical experience.
Use consistent exposure metrics such as patient-years (number of patients × years of device use), device-years, or episodes of use. Choose the most appropriate metric for your device type and maintain consistency throughout your PSUR for meaningful trend analysis. Document your calculation methodology.
Immediately assess the clinical significance and implement appropriate risk mitigation measures. This may require updating labeling, implementing additional risk controls, conducting enhanced surveillance, or in severe cases, market withdrawal. Notify your notified body and relevant authorities promptly.
Device grouping is acceptable when devices share similar safety profiles, have equivalent clinical performance, and address the same medical conditions. Provide clear justification for grouping decisions and identify the leading device for the group. Separate analysis may be required if safety profiles diverge.
Use methods appropriate for your data characteristics: Poisson regression for incident rates, Mann-Kendall tests for non-parametric trends, or time-series analysis for complex patterns. Establish significance thresholds (typically p \< 0.05) and consider clinical significance alongside statistical significance.
PSUR frequency is determined during conformity assessment but typically ranges from annual to every five years depending on device risk, clinical experience, and market maturity. High-risk or novel devices typically require more frequent reporting than well-established technologies with extensive clinical history.